6,534 Shares in Revolution Medicines, Inc. $RVMD Bought by Sanctuary Advisors LLC

Sanctuary Advisors LLC bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,534 shares of the company’s stock, valued at approximately $1,224,000.

Other institutional investors also recently bought and sold shares of the company. Meeder Advisory Services Inc. lifted its holdings in Revolution Medicines by 3.0% in the 1st quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock worth $401,000 after purchasing an additional 120 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Revolution Medicines by 1.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock valued at $802,000 after purchasing an additional 125 shares during the period. Deutsche Bank AG lifted its stake in shares of Revolution Medicines by 0.4% in the fourth quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock worth $2,566,000 after buying an additional 130 shares during the last quarter. Contravisory Investment Management Inc. acquired a new stake in shares of Revolution Medicines in the second quarter worth $32,000. Finally, Johnson Financial Group Inc. bought a new stake in shares of Revolution Medicines during the 2nd quarter worth $37,000. 94.34% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wolfe Research reiterated an “outperform” rating and issued a $220.00 target price on shares of Revolution Medicines in a report on Monday, August 10th. Evercore restated an “outperform” rating and set a $320.00 price target on shares of Revolution Medicines in a report on Thursday. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $248.00 price target on shares of Revolution Medicines in a research report on Thursday. Royal Bank Of Canada lifted their price objective on Revolution Medicines from $203.00 to $251.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Truist Financial boosted their price objective on Revolution Medicines from $231.00 to $239.00 and gave the stock a “buy” rating in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $193.28.

Revolution Medicines Price Performance

NASDAQ:RVMD opened at $221.15 on Friday. The stock has a market cap of $47.40 billion, a P/E ratio of -25.07 and a beta of 1.39. Revolution Medicines, Inc. has a one year low of $37.56 and a one year high of $224.31. The company has a fifty day moving average price of $192.43 and a 200 day moving average price of $148.17. The company has a debt-to-equity ratio of 0.40, a current ratio of 11.38 and a quick ratio of 11.38.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.02). During the same quarter in the previous year, the company earned ($1.31) EPS. Analysts anticipate that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.

Insider Buying and Selling at Revolution Medicines

In related news, insider Stephen Michael Kelsey sold 4,175 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $156.12, for a total value of $651,801.00. Following the completion of the sale, the insider owned 291,876 shares in the company, valued at approximately $45,567,681.12. This trade represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jack Anders sold 20,000 shares of Revolution Medicines stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the sale, the chief financial officer directly owned 123,269 shares in the company, valued at approximately $20,749,870.77. This trade represents a 13.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 212,497 shares of company stock valued at $38,206,486 in the last three months. Company insiders own 7.60% of the company’s stock.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.